FDA announces safety labeling changes for opioids to tackle misuse

11 September 2013

The US Food and Drug Administration has announced safety labeling changes and post-market study requirements for extended-release and long-acting opioid analgesics.

The new regulations aim to cut the number of deaths per year from opioid dependence. Earlier this year the Center for Disease Control’s Vital Signs report showed that prescription painkiller overdoses killed nearly 48,000 women between 1999 and 2010 ( The Pharma Letter July 3).

The class-wide labeling changes will include important new language to help health care professionals tailor their prescribing decisions based on a patient’s individual needs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical